StockData
Prime Medicine, Inc. logo

Prime Medicine, Inc. (PRME) stock

PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.82−0.02 (-0.52%)

Close on Nov 18, 2026Market cap $692.86MP/E –Yield –

Prime Medicine revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Prime Medicine's revenue for the twelve months ending Dec 31, 2025 was $4.63M, up 55.3% year over year. For fiscal 2025 it was $4.63M, up 55.3% from the year before. The highest annual figure on record is $5.21M in fiscal 2020.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.63M+55.3%
FY2024Dec 31, 2024$2.98M–
FY2023Dec 31, 2023$0–
FY2022Dec 31, 2022$0–
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$5.21M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$838.00K-61.6%
Q3 FY2025Sep 30, 2025$1.23M+486.1%
Q2 FY2025Jun 30, 2025$1.12M–
Q1 FY2025Mar 31, 2025$1.45M+146.0%
Q4 FY2024Dec 31, 2024$2.18M–
Q3 FY2024Sep 30, 2024$209.00K–
Q2 FY2024Jun 30, 2024$0–
Q1 FY2024Mar 31, 2024$591.00K–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023$0–

More Prime Medicine figures

See a number that looks wrong?